Efficacy of rituximab in refractory RRMS

Abstract

Objective:

To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modifying therapy (DMT).

Methods:

In this observational nationwide retrospective multicenter study, we first identified 351 off-label rituximab-treated patients through a cohort of 15,984 RRMS patients. In this group, we identified patients with disease activity prior to rituximab confirmed by MRI (one or more new T2 lesion and/or gadolinium-enhancing lesion) despite immunosuppressive DMT (fingolimod, natalizumab, or mitoxantrone) with a follow-up after rituximab initiation longer than 6 months. Outcome data were collected from the French Observatory of Multiple Sclerosis (OFSEP) register and medical charts.

Results:

A total of 50 patients were identified. Median rituximab treatment duration was 1.1 (0.5–6.4) year. Mean annualized relapse rate significantly decreased from 0.8 during last immunosuppressive DMT to 0.18 after rituximab (p < 0.0001). While 72% of patients showed gadolinium-enhancing lesions on the last MRI performed during last immunosuppressive DMT, 8% of them showed gadolinium-enhancing lesions on the first MRI performed 6.1 (range 1.4–18.4) months after rituximab (p < 0.0001).

Conclusion:

This study provides level IV evidence that rituximab reduces clinical and MRI disease activity in patients with active RRMS despite immunosuppressive DMT.

Keywords

Multiple sclerosis relapsing/remitting treatment response second-line treatment disease-modifying therapies

Get full access to this article

View all access options for this article.

References

Bar-Or

Calabresi

PAJ

Arnold

et al . Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008; 63(3): 395–400.

Hauser

Waubant

Arnold

et al . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358(7): 676–688.

Naismith

Piccio

Lyons

et al . Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010; 74(23): 1860–1867.

Kappos

Calabresi

et al . Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378(9805): 1779–1787.

Hauser

Bar-Or

Comi

et al . Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376(3): 221–234.

Alping

Frisell

Novakova

et al . Rituximab versus fingolimod after natalizumab in multiple sclerosis patients: Rituximab vs fingolimod. Ann Neurol 2016; 79(6): 950–958.

Salzer

Svenningsson

Alping

et al . Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87(20): 2074–2081.

Spelman

Frisell

Piehl

et al . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler 2018; 24: 1087–1095.

Pucci

Giuliani

Solari

et al . Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011; 10: CD007621.

10.

Butzkueven

Kappos

Pellegrini

et al . Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85(11): 1190–1197.

11.

Hartung

H-P

Gonsette

König

et al . Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360(9350): 2018–2025.

12.

van de Wyngaert

Beguin

D’Hooghe

et al . A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001; 101(4): 210–216.

13.

van Vollenhoven

Fleischmann

Furst

et al . Longterm safety of rituximab: Final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. J Rheumatol 2015; 42(10): 1761–1766.

14.

Tony

H-P

Burmester

Schulze-Koops

et al . Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther 2011; 13(3): R75.